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South Africa has one of the fastest-growing HIV-infected 
populations in the world. While the rollout of antiretroviral 
(ARV) therapy has brought much excitement and hope to 
both patients and practitioners, it has also brought many 
new questions and challenges. Adherence and regular clinic 
attendance are two of these challenges. This study attempted to 
trace patients at Themba Lethu Clinic, Helen Joseph Hospital, 
Johannesburg, who had been lost to follow-up, and to explore 
the reasons for non-attendance. Lost-to-follow-up patients 
were defined as those who had missed a clinic visit and who 
had not presented to the clinic within 1 month of the missed 
date. Adherence was defined as the correct and timely dosing 
of prescribed medications. The literature reviewed does not 
differentiate between the two definitions as patients in those 
studies were traced via pharmacy records – those who did not 
collect pharmacy prescriptions were assumed to be both non-
adherent and lost to follow-up.
While adherence has always been viewed as a very 
important principle, it may be more critical than previously 
thought.  Wood et al.1 evaluated the effect of baseline CD4+ 
count and adherence on survival rates in an attempt to 
determine when to initiate highly active antiretroviral therapy 
(HAART). They found an increase in mortality when initiating 
at CD4 counts less than 200 cells/µl, but more importantly 
provided evidence that adherence was a statistically significant 
determinant of outcome at all CD4+ strata.
One of the more concerning outcomes related to poor 
adherence is the development of drug-resistant viral strains. 
Sethi et al.2 sought to define the level of adherence associated 
with the greatest risk of resistance. The conclusion was that 
the greatest risk of clinically significant viral resistance occurs 
after missing 11 - 30% of ARV doses. No resistance was noted 
in patients with a cumulative adherence of less than 60%. That 
paper2 emphasised that poor adherence is associated with 
viral failure, but not necessarily resistance. The greatest risk of 
resistance was with the reasonably adherent patient.
Many theories have been postulated regarding the main 
causes of non-adherence and various studies in different 
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Background. Patients who do not return for follow-up at clinics 
providing comprehensive HIV/AIDS care require special 
attention.  This is particularly true where resources are limited 
and clinic loads are high. Themba Lethu Clinic at Helen Joseph 
Hospital in Johannesburg is a facility supported by PEPFAR 
funding through Right to Care (Grant CA-574-A-00-02-00018); 
more than 800 HIV/AIDS patients are seen there each week. 
Data on a sample of patients who failed to return for follow-up 
were analysed to identify the causes and to plan strategies to 
overcome the problem.
Methods. A group of 182 patients who missed follow-up 
appointments at the clinic were identified. Their files were 
examined to identify possible contributing factors. The patients 
were then contacted telephonically and asked their reasons for 
non-attendance. 
Results. Results show that the leading cause of failure to follow 
up was financial (34% of patients). Patients cited transport 
costs and having to pay to open a file at each visit as the 
biggest monetary obstacles to obtaining treatment. Fifty-five 
per cent of patients lost to follow-up showed an improvement 
in CD4 count on treatment. Death accounted for 27% of the 
patients lost to follow-up and the mean (± standard deviation 
(SD)) duration of treatment in this group was only 8 (± 6) 
weeks. Of the patients in this group who had been seen at 4 
months, 60% had failed to respond to treatment. The mean 
duration of ARV treatment before being lost to follow-up was 
21 (± 28) weeks. The mean CD4+ count was 92 (± 74.5) cells/µl 
and the mean number of visits was 3.33 (± 2.17). Seventy-four 
per cent of the patients were on regimen 1A, and only 1 cited 
side-effects of medication as a reason for not returning. 
Conclusions. This study highlighted financial difficulty as the 
major obstacle to obtaining treatment. There is evidence in 
support of providing ARV treatment free of charge to HIV-
positive patients who qualify, as occurs in other provinces in 
South Africa. It is also suggested that providing ARV therapy 
at more local clinics in the community would make treatment 
more accessible. Provision of several months’ supply of 
medicines per visit would help to reduce transport costs and 
minimise patient expenditure. These interventions may reduce 
the incidence of patients lost to follow-up in this community.
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communities have found a multitude of reasons. Many ARV 
regimens are complicated and have a high pill burden. There 
are multiple adverse side-effects associated with the drugs as 
well as interactions with other chronic medications. This may 
make compliance difficult for patients and may result in viral 
failure, development of drug resistance and limited future 
treatment options. 
Trotta et al.3 investigated which regimens were associated 
with the poorest rates of adherence and found that protease 
inhibitor (PI)-treated patients were the poorest adherers, while 
non-nucleoside reserve transcriptase inhibitors (NNRTI)-
treated patients, especially those on efavirenz, were most 
adherent. Vomiting and sexual dysfunction while on PIs were 
identified as the main reasons for non-adherence.
Schiller4 also studied the effect of adverse drug effects 
and compliance and found that 50% of patients in the study 
experienced adverse drug effects and it was the most common 
reason given for non-adherence in those patients. Most organ 
systems can be affected, depending on the drug or class of 
drugs being used; proper identification of adverse effects 
can therefore be difficult. The most common adverse effects 
suffered include gastrointestinal, neurological, metabolic, and 
cardiovascular events, although renal, dermatological, and 
haematological events may also occur. 
While nausea, vomiting and anorexia appear to be the most 
common side-effects reported, diarrhoea was found to be a 
negative predictor of survival in HIV-positive individuals as it 
was associated with poor quality of life and poor adherence to 
treatment.
Adverse-effect management has included treatment 
interruptions and therapeutic drug monitoring, but it most 
commonly involves switching to another drug or class of 
drugs. This requires a complete understanding of HAART 
regimens and their associated complications. Schiller4 found 
that HIV clinics employing clinical pharmacists were able to 
prevent adverse effects by suggesting alternative treatments, 
and by introducing medication counselling and compliance 
education.
Lignani et al.5 concurred with these findings. They concluded 
that the main cause of treatment failure was medication 
side-effects. Education level and age were also identified as 
important predictors of compliance with ARV therapy.
However, a study done in Brazil by Monreal et al.6 found 
adverse effects to be only the third most important reason for 
non-compliance. Forgetfulness was the most common reason 
given by patients, followed by running out of medication. 
Other predictors of poor compliance identified were 
complexity of dosing regimens and pill fatigue.
A Canadian study by Veinot et al.7 found that youth (aged 
18 to 25 years) were particularly prone to poor compliance. 
Reasons included scepticism about the efficacy of medication, 
costs involved, stigma of disease and ‘feeling different’ as well 
as confusion about how to take the medication. The authors 
concluded that this age group may require developmentally 
appropriate, empowerment-based treatment approaches to 
help with treatment difficulties and adherence.
Another group prone to adherence problems are those with 
low literacy levels. Kalichman et al.8 found that people living 
with HIV/AIDS who have lower health literacy show poorer 
treatment adherence and more adverse health outcomes.
The authors designed a two-session plus one booster session 
nurse-delivered HIV treatment adherence intervention. Results 
from a pilot test involving 30 HIV-positive men and women 
showed that the nurse-delivered programmes increased 
HIV/AIDS knowledge, intention to improve adherence, and 
self-motivation for adhering to medications. Participants also 
showed improvement in medication adherence, with reduction 
in number of missed pills and reduction in number of doses 
taken at the wrong time.
However, patients with good educational levels are not 
without adherence problems. Moyle9 studied compliance in 
an Edinburgh-based population and found that while higher 
educational level was associated with better adherence, such 
patients still had difficulty with work-time dosing as well as 
with depression and negative thoughts about treatment. It was 
found that patient knowledge of improved CD4+ count and 
viral load results had a positive impact on adherence.
In conclusion, factors associated with poor adherence have 
no social or cultural borders, and this should be kept in mind 
when attempting to find solutions to adherence problems. 
Patient counselling on correct dosing and motivation through 
periods of ‘pill fatigue’ are vital. There is good evidence for 
simplifying regimens. Any intervention must be appropriate to 
the social and cultural norms of the target population and must 
cater for differing literacy and educational levels.
Materials and methods 
We identified a group of 182 patients who missed follow-up 
appointments at the clinic, and over a period of 2 months 
we examined their files for information such as gender, age, 
number of visits, most recent CD4+ count and viral load, ARV 
regimen and whether or not they were receiving a disability 
grant. We developed an interview questionnaire designed 
for telephonic use. The patients were was then contacted 
telephonically and asked their reasons for not attending 
their scheduled clinic visit, and also if they would consider 
returning to the clinic to attempt to resolve any problems 
identified. No controls were used. 
Data were entered into a spreadsheet and were analysed 
using Microsoft Excel and SAS statistical software.  
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Results 
Of the total number of clinic attendees (N = 5 849), 182 were 
recorded as having missed a clinic visit. We excluded 28 of 
these from statistical analysis as duplicate files were discovered 
for these people, i.e. the patients were not actually lost to 
follow-up. The final population group therefore totalled 154 (89 
females and 65 males).
Of these, a further 84 patients had either incorrect contact 
details or no contact details recorded in their files and were 
therefore uncontactable.
Seventy patients were contacted and gave reasons for their 
lack of follow-up. Fig. 1 is the pie chart representation of 
the reasons given. The most common reason was financial 
difficulty, followed closely by death of the patient. Of 
the 19 patients found to have died, only 4 had illnesses 
recorded at the last visit. Two had proven tuberculosis, 1 had 
cytomegalovirus (CMV) retinitis and 1 had hepatitis B. The 
mean (± standard deviation (SD)) duration of treatment in 
this group was only 8 (± 6) weeks, and of the patients in this 
group who were seen at 4 months, 60% had failed to respond 
to treatment.
Eleven per cent of patients said that their medication had 
been stopped by their attending doctor but none knew the 
reason for the interruption in treatment.
Other reasons given included change of residence, with 
patients now receiving treatment from another facility, 
commencement of medical aid and private treatment, social 
problems such as incarceration, and the decision to try 
traditional medicine. Only 1.4% (N = 1) complained of side-
effects.
Data obtained from the files of the group without correct 
contact details were included in the rest of the statistical 
analysis as these patients were believed to be genuinely lost to 
follow-up.
ARV regimen
Fig. 2 shows the distribution of the ARV regimens used by the 
patients. The majority of patients (74%) were on regimen 1A 
(stavudine, lamivudine and efavirenz). 
The mean number of weeks on treatment (± SD) was 21 (± 
28) weeks, and the mean number of visits was 3. 33 (± 2.17) 
visits.
CD4 counts
The mean baseline CD4 count for all patients was 92 (± 74.5) 
while the last recorded CD4 count showed a mean of 199.9 
(± 136.8). Note that we were only able to calculate this value 
for those patients who had attended more than 1 clinic visit 
(N = 83). 
We then calculated the mean CD4 baseline, the mean last 
recorded CD4 level and the mean response to treatment 
(increase in CD4 count since initiation of treatment) for 2 
groups, viz. the deceased patients (N = 19) and the patients 
who were still alive (N = 133). Two patients did not have 
recorded CD4 counts. Table I shows the comparative results. 
There seemed to be a trend in the results suggesting lower 
baseline CD4 counts in the deceased patients and also less of 
an increase in CD4 count on treatment for those who were 
deceased. A t-test done on these results showed no statistical 
significance; however a larger sample size may have shown the 
trend to be significant.
Age 
The mean age of the study group was 35.3 (± 7.8) years for 
females and 38.4 (± 6.8) years for males. This correlated with 
the mean ages in the general clinic population.
Gender
We then compared the CD4 count variables (CD4 baseline, last 
recorded CD4 count and CD4 count response) across genders. 
This time there were statistically significant differences. The 
female patients had higher mean baseline CD4 counts and 
showed better CD4 responses once initiated on treatment 
than their male counterparts. The females had also been on 
Fig. 1. Reasons given for loss to follow-up.
Fig. 2. Distribution of ARV regimens.
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treatment for longer and had a higher mean number of visits. 
These results are summarised in Table II.
While fewer in number than females overall in this study, 
the males showed an increased representation in the study 
(42%) compared with the overall proportion in the clinic (30%). 
A chi-squared test showed this comparison to be statistically 
significant (x2 = 7.15, p = 0.01 < 0.005).
Limitations 
The lack of contact details in the files of some of the study 
group limited the study considerably. The study may also 
have been limited by the fact that all interviews were done 
telephonically and the location of the patient during the 
interview may have precluded them from speaking freely.
Discussion 
One of the most significant results of this study was the 
staggering number of patients who could not be contacted 
because of lost files, incorrect contact details in files or no 
contact details recorded at all. Files that were available often 
had information missing, even information crucial to the 
patients’ follow-up such as baseline CD4 counts and date 
initiated on therapy. This problem involved a number of 
factors. At the time of the study the clinic was largely reliant 
on paper files to keep patient details and records. Such files are 
easily lost when patients visit other clinics or get prescriptions 
filled. Duplicate files are made, but often information such as 
contact details, past visits and blood results are not recorded 
in those new files. The other factor to be considered is the 
level of mobility of this population sample. Most patients give 
only a cell phone number as a contact as they do not have a 
permanent residential address. Many frequently move around 
in search of work or on contract work. Additionally, often an 
entire family shares one cellphone and it is difficult to contact 
a specific member, especially with confidential or sensitive 
information. Many people change their cell numbers frequently 
because of theft or expiration of the sim card airtime window 
(usually 12 months).
The financial difficulties experienced by the population 
group in this study were clear, as financial difficulty was the 
most commonly cited reason for not returning for clinic visits. 
Patients at the clinic have to pay a fee every time they open 
their file to visit the doctor. Additionally, many patients travel 
long distances to get to the clinic as ARVs are not available at 
their local clinics, and transport costs are high. 
For some patients, fear of disclosing their HIV status, 
especially to employers or colleagues, led to difficulty in 
obtaining and using treatment correctly. Patients feared 
dismissal if employers found out that were using ARVs and 
battled to hide their bottles of pills at work. Kaletra was 
particularly problematic as it must be kept refrigerated, which 
was impossible for those whose workplaces had no refrigerator 
Table I. Comparative CD4 counts (deceased v. alive)
Variable  Alive N Mean       SD             SEM Minimum Maximum
CD4 baseline No   19 61.526       65.962             15.133         2        196
CD4 baseline Yes 133 97.752       81.201             7.041         1        533
CD4 last  No    8 151.88       138.9             49.11       12        446
CD4 last  Yes  75 204.88       135.62             15.66         4        544
CD4 response No    8 2.4211       68.749             15.772      –95        250
CD4 response Yes            75 17.519       133.79             11.515    –276        340
SD = standard deviation; SEM = standard error of the mean. 
Table II. CD4 counts according to gender
Variable  Sex N Mean       SD             SEM Minimum Maximum
CD4 baseline F 89 100.41       80.127             8.5416        1        533
CD4 baseline M 63 84.048       80.235            10.109        2        462
CD4 last  F 51 228.24       144.55            20.443        4        544
CD4 last  M 32 157.44       112.14             19.825      10        474
CD4 response F 51 29.273       134.96             14.386  –210        340
CD4 response M 32 –3.954       115.63             14.342  –276        291
Visits  F 89 3.5955       2.1305            0.2258        1          10
Visits  M 65 2.9844       2.2002            0.275        1           11
Weeks on ARVs F 89 23.9       31.3             3.3        0        242
Weeks on ARVs M 65 17.7       23.1             2.9        0        114
     
SD = standard deviation; SEM = standard error of the mean; ARVs = antiretrovirals. 
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and very awkward for those who shared communal 
refrigerators.  Timing of medication at work was problematic 
for patients who relied on public transport, as the unreliability 
of the latter meant they either got to work late to take their 
tablets or got home late for the evening dose. Even those 
patients who were open about their status with their employers 
felt that the clinic visits were too frequent (they must attend 
every month to collect medication even if they are not due for 
a doctor’s visit) and long queues at clinics and the pharmacy 
meant missing an entire day’s work.
Death of the patient was the second most frequent reason for 
loss to follow-up. However the results showed that there was 
a trend of low baseline CD4 counts and a poorer response to 
treatment suggesting that those patients who died on treatment 
sought help late and were already quite ill. Although we could 
not prove statistical significance, if the sample size was larger 
this apparent trend might have proved to be more significant. 
The discrepancy in CD4 count between the genders was 
interesting as none of the literature reviewed showed any 
gender differences in ARV compliance. A much greater 
proportion of men were lost to follow-up than expected. 
Additionally, the female subjects demonstrated higher baseline 
CD4 counts and better CD4 responses while on treatment. 
The mean number of weeks on treatment was also greater 
in females. These findings suggest differences in attitudes to 
health and help-seeking behaviour between the genders, with 
women seeking help earlier and showing better compliance 
on treatment than their male counterparts. This may be related 
simply to male reluctance to seek help, or there may be a 
more socially rooted cause. The men in this study were more 
likely to be employed than the women, and taking a full day’s 
leave every month consecutively for several months may have 
put their jobs at risk. For the contract or casual worker, the 
situation may have been even more difficult as missing a day’s 
work would mean losing out on wages for the time missed or 
even loss of a contract completely. 
Age was not found to be a significant predictor of clinic 
attendance.
The results of this study did not correlate with the findings 
of the reviewed literature concerning drug side-effects. Only 
1 patient stopped his ARVs because of problems with side-
effects. He developed hepatotoxity while on nevirapine and 
discontinued treatment after a hospital admission. The reason 
for this discrepancy may be that the population group in this 
study was more stoic in character than other study groups, or 
it may be that their financial worries dwarfed other problems 
that they were experiencing. None complained that the dosing 
regimen was too complex.
Conclusion
Strategies to improve adherence in this group must take into 
account the financial stresses of this population, particularly 
the male population. Strategies may include making ARV 
therapy free of charge and extending the rollout of ARVs 
to more local clinics. In this way patients could access their 
medication closer to their homes, reducing transport costs and 
reducing the number of clinic visits. Until this rollout happens, 
dispensing several months’ worth of medication between 
doctors’ visits would also mean fewer trips to the clinic. 
However these initiatives could only be considered for the 
well patient who does not require frequent medical check-up, 
and each patient’s circumstances would have to be assessed 
individually.
In conclusion, it must be emphasised that differences in 
social status should be taken into consideration when initiating 
patients on ARV therapy. Each population has its own 
difficulties and attitudes towards treatment and these must 
be weighed carefully when considering strategies to ensure 
adherence. 
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